Fischer Laura E, Wolfe Bruce M, Fino Nora, Elman Miriam R, Flum David R, Mitchell James E, Pomp Alfons, Pories Walter J, Purnell Jonathan Q, Patti Mary-Elizabeth
Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Departments of Medicine, Surgery, and the School of Public Health at Oregon Health & Science University, Portland, Oregon.
Surg Obes Relat Dis. 2021 Oct;17(10):1787-1798. doi: 10.1016/j.soard.2021.04.021. Epub 2021 May 19.
Postbariatric hypoglycemia (PBH) can be a devastating complication for which current therapies are often incompletely effective. More information is needed regarding frequency, incidence, and risk factors for PBH.
To examine hypoglycemia symptoms following Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB) and baseline and in-study risk factors.
Multicenter, at 10 US hospitals in 6 geographically diverse clinical centers.
A prospective, longitudinal cohort study of adults undergoing RYGB or LAGB as part of clinical care between 2006 and 2009 were recruited and followed until January 31, 2015, with baseline and annual postoperative research assessments. We analyzed baseline prevalence and post-operative incidence and frequency of self-reported hypoglycemia symptoms as well as potential preoperative risk factors.
In all groups, postoperative prevalence of hypoglycemia symptoms was 38.5%. Symptom prevalence increased postoperatively from 2.8%-36.4% after RYGB in patients without preoperative diabetes (T2D), with similar patterns in prediabetes (4.9%-29.1%). Individuals with T2D had higher baseline hypoglycemia symptoms (28.9%), increasing after RYGB (57.9%). Hypoglycemia symptoms were lower after LAGB, with 39.1% reported hypoglycemia symptoms at only 1 postoperative visit with few (4.0%) having persistent symptoms at 6 or more annual visits. Timing of symptoms was not restricted to the postprandial state. Symptoms of severe hypoglycemia were reported in 2.6-3.6% after RYGB. The dominant risk factor for postoperative symptoms was preoperative symptoms; additionally, baseline selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitor use was also associated with increased risk in multivariable analysis. Weight loss and regain were not related to hypoglycemia symptom reporting.
Hypoglycemia symptoms increase over time after RYGB, particularly in patients without diabetes. In a small percentage, symptoms can be persistent or severe and require hospitalization. Preoperative hypoglycemia symptoms and SSRI/SNRI use in RYGB patients without diabetes is associated with increased risk of symptoms.
减重术后低血糖(PBH)可能是一种严重的并发症,目前的治疗方法往往效果不完全理想。关于PBH的发生率、发病率和危险因素,还需要更多信息。
研究Roux-en-Y胃旁路术(RYGB)和腹腔镜可调节胃束带术(LAGB)后的低血糖症状以及基线和研究期间的危险因素。
美国6个地理位置不同的临床中心的10家医院组成的多中心研究。
对2006年至2009年期间接受RYGB或LAGB作为临床治疗一部分的成年人进行一项前瞻性纵向队列研究,招募并随访至2015年1月31日,进行基线和术后年度研究评估。我们分析了自我报告的低血糖症状的基线患病率、术后发病率和频率以及潜在的术前危险因素。
在所有组中,术后低血糖症状的患病率为38.5%。在无术前糖尿病(T2D)的患者中,RYGB术后症状患病率从2.8% - 36.4%增加,糖尿病前期患者有类似模式(4.9% - 29.1%)。患有T2D的个体基线低血糖症状较高(28.9%),RYGB术后增加(57.9%)。LAGB术后低血糖症状较低,只有39.1%的患者在术后仅一次就诊时报告有低血糖症状,很少(4.0%)患者在6次或更多次年度就诊时有持续症状。症状出现时间不限于餐后状态。RYGB术后2.6% - 3.6%的患者报告有严重低血糖症状。术后症状的主要危险因素是术前症状;此外,在多变量分析中,基线使用选择性5-羟色胺再摄取抑制剂(SSRI)和5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)也与风险增加有关。体重减轻和恢复与低血糖症状报告无关。
RYGB术后低血糖症状随时间增加,尤其是在无糖尿病患者中。一小部分患者症状可能持续或严重,需要住院治疗。RYGB无糖尿病患者术前低血糖症状和使用SSRI/SNRI与症状风险增加有关。